De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary tract cancers. N Engl J Med. 1999, 341: 1368-78. 10.1056/NEJM199910283411807.
Article
CAS
PubMed
Google Scholar
Gores GJ: Cholangiocarcinoma: current concepts and insights. Hepatology. 2003, 5: 961-9. 10.1053/jhep.2003.50200.
Article
Google Scholar
Rajagopalan V, Daines WP, Grossbard ML, Kozuch P: Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Huntingt). 2004, 18: 889-96.
Google Scholar
Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacollogically directed design of the dose rate and schedule of 2, 2-dideoxy-fluorocytidine (Gemcitabine) administration in leukemia. Cancer Res. 1990, 50: 6823-6.
CAS
PubMed
Google Scholar
Plunkett W, Huang P, Searcy CE, Gandhi V: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol. 1996, 23: 3-15.
CAS
PubMed
Google Scholar
Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol. 1995, 22: 42-6.
CAS
PubMed
Google Scholar
Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJ, Pinedo HM, Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2, 2-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol. 1996, 38: 335-42. 10.1007/s002800050492.
Article
CAS
PubMed
Google Scholar
Eckel F, Lersch C, Assmann G, Schulte-Frohlinde E: Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: A pilot study. Cancer Invest. 2002, 20 (2): 180-5. 10.1081/CNV-120014881.
Article
CAS
PubMed
Google Scholar
Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C: Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest. 2003, 21: 690-4. 10.1081/CNV-120023767.
Article
CAS
PubMed
Google Scholar
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000, 92 (3): 205-16. 10.1093/jnci/92.3.205.
Article
CAS
PubMed
Google Scholar
Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clinical trials. 1989, 10: 1-10. 10.1016/0197-2456(89)90015-9.
Article
CAS
PubMed
Google Scholar
Eckel F, Lersch C, Assmann G, Schulte-Frohlinde E: Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer. Ann Oncol. 2000, 11: 762-3. 10.1023/A:1008368611993.
Article
CAS
PubMed
Google Scholar
Daines WP, Rajagopalan V, Grossbard ML, Kozuch P: Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2. Oncology (Huntingt). 2004, 18: 1049-59.
Google Scholar
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997, 15: 2403-13.
CAS
PubMed
Google Scholar
Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003, 21 (18): 3402-8. 10.1200/JCO.2003.09.140.
Article
CAS
PubMed
Google Scholar
Metzger J, Sauerbruch T, Ko Y, et al: A phase II trial of gemcitabine in gallbladder and biliary tract carcinomas. Onkologie. 1998, 21: 232-4. 10.1159/000026821.
Google Scholar
Verderame F, Mandina P, Abruzzo F, Scarpulla M, Di Leo R: Biliary tract cancer: our experience with gemcitabine treatment. Anticancer Drugs. 2000, 11 (9): 707-8. 10.1097/00001813-200010000-00006.
Article
CAS
PubMed
Google Scholar
Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML, Valdesi M: Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001, 19 (20): 4089-91.
CAS
PubMed
Google Scholar
Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001, 12 (2): 183-6. 10.1023/A:1008352123009.
Article
CAS
PubMed
Google Scholar
Lin MH, Chen JS, Chen HH, Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy. 2003, 49 (3): 154-8. 10.1159/000070622.
Article
CAS
PubMed
Google Scholar
Eng C, Ramathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL: A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol. 2004, 27 (6): 565-9. 10.1097/01.coc.0000135924.94955.16.
Article
CAS
PubMed
Google Scholar
Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E: Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004, 22 (2): 193-8. 10.1023/B:DRUG.0000011797.09549.53.
Article
CAS
PubMed
Google Scholar
Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH: Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol. 2005, 35 (2): 68-73. 10.1093/jjco/hyi021.
Article
PubMed
Google Scholar